Quinoxalines (including Hydrogenated) Patents (Class 544/353)
-
Patent number: 8580785Abstract: Compounds of formula (I), wherein the substituents are as defined in claim (1), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 14, 2006Date of Patent: November 12, 2013Assignee: Syngenta Crop Protection LLCInventors: André Jeanguenat, Roger Graham Hall, Olivier Loiseleur, Stephan Trah, Patricia Durieux, Andrew Edmunds, André Stoller
-
Publication number: 20130296557Abstract: The present invention relates to novel diarylacetylene hydrazide compounds of formula (I) or pharmaceutically acceptable salt thereof, as tyrosine kinase inhibitors, the process for their preparation, and to the use of the compounds of formula (I) in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to tyrosine kinases, in warm-blooded animalsType: ApplicationFiled: January 23, 2012Publication date: November 7, 2013Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Prabal Sengupta, Hemant Ashvinbhai Chokshi, Chetan Surjitsingh Puri, Sabbirhusen Yusufbhai Chimanwala, Varun Anilkumar Mehta, Dipali Manubhai Desai, Trinadha Rao Chitturi, Rajamannar Thennati
-
Publication number: 20130292663Abstract: To provide an organic compound of excellent characteristics that exhibits excellent electron-injecting/transporting performance with hole blocking ability, and has high stability in the thin-film state, as material for an organic electroluminescent device having high efficiency and high durability, and to provide the organic electroluminescent device having high efficiency and high durability using the compound. An organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, wherein the compound of general formula (1) in which a substituted bipyridyl group and a pyridoindole ring structure are bonded via a phenylene group, is used as a constituent material of at least one organic layer.Type: ApplicationFiled: January 16, 2012Publication date: November 7, 2013Applicant: HODOGAYA CHEMICAL CO., LTD.Inventors: Norimasa Yokoyama, Daizou Kanda, Shuichi Hayashi, Eiji Takahashi
-
Patent number: 8575203Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.Type: GrantFiled: April 19, 2011Date of Patent: November 5, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Harald Engelhardt, Christiane Kofink, Darryl McConnell
-
Publication number: 20130289041Abstract: Disclosed herein are compounds of formula (I) and methods of inhibiting IKK? and the NF-?B signaling and mTOR pathways.Type: ApplicationFiled: November 22, 2011Publication date: October 31, 2013Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Amarnath Natarajan, Qianyi Chen, Vashti C. Bryant, Rajkumar Rajule
-
Publication number: 20130281445Abstract: The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.Type: ApplicationFiled: September 21, 2012Publication date: October 24, 2013Inventors: Simon Everitt, Ronald Knegtel, Michael Mortimore, Alistair Rutherford
-
Publication number: 20130274471Abstract: A compound for an organic photoelectric device, an organic photoelectric device including the same, and a display device including the same the compound being represented by the following Chemical Formula 1:Type: ApplicationFiled: June 12, 2013Publication date: October 17, 2013Inventors: Kyu-Yeon IN, Myeong-Soon KANG, Ho-Kuk JUNG, Nam-Soo KIM, Eui-Su KANG, Mi-Young CHAE, Jin-Seong PARK
-
Patent number: 8557987Abstract: The present invention relates to optoelectronic materials field, and it discloses a benzodithiophene organic semiconductive material with the following structural formula (P): wherein, x+y=2; 1?x<2, 0<y?1; 1<n?100; R1, R2 are C1-C20alkyl; R3 is selected from C1-C20alkyl; R4, R5 are hydrogen, phenyl, C1-C20 alkyl or phenyl substituted by C1-C20 alkoxy. The present invention is also provided with preparation method and use of the benzodithiophene organic semiconductive material. The benzodithiophene containing bisphenyl siloles unit has good dissolution property, high carrier mobility, strong absorbance, wide optical absorption range, and improved utilization of sunlight, and its preparation process is simple, with high yield, and easy to operate and control.Type: GrantFiled: September 10, 2010Date of Patent: October 15, 2013Assignee: Ocean's King Lighting Science & Technology Co., Ltd.Inventors: Mingjie Zhou, Jie Huang, Erjian Xu
-
Publication number: 20130267525Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: November 29, 2011Publication date: October 10, 2013Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Steven John Woodhead, Yannick Aime Eddy Ligny, Patrick René Angibaud
-
Patent number: 8551992Abstract: Oxazole derivatives are described. The inventive compounds are useful as kinase inhibitors, and may be used in the treatment of cancer, such as prostate cancer, lung cancer, breast cancer, colon cancer, leukemia, CNS cancer, melanoma, ovarian cancer, and renal cancer.Type: GrantFiled: May 23, 2012Date of Patent: October 8, 2013Assignee: Neosome Life Sciences, LLCInventors: Laxman S. Desai, Srinivas Chittaboina
-
Publication number: 20130261081Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).Type: ApplicationFiled: September 12, 2011Publication date: October 3, 2013Inventors: Nobuaki Ito, Hirofumi Sasaki, Kuninori Tai, Tomoichi Shinohara
-
Publication number: 20130261123Abstract: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.Type: ApplicationFiled: December 16, 2011Publication date: October 3, 2013Inventors: Xicheng Sun, Jian Qiu, Adam Stout
-
Patent number: 8530658Abstract: Disclosed is a carbazole derivative and a light-emitting element, a light-emitting device, and an electronic device using thereof. The carbazole derivative possesses an oxadiazole moiety or a quinoxaline moiety as a heteroaromatic ring having an electron-transporting property and a carbazole moiety having a hole-transporting property. The ability of the carbazole derivative to transport both electrons and holes and its large excitation energy larger than a triplet excitation energy of a phosphorescent compound allow the formation of a phosphorescent light-emitting element having well-controlled carrier balance, which contributes to the formation of light-emitting devices and electronic devices that are capable of being driven at a low voltage, have a long lifetime, and consume low power. The detailed structure of the carbazole derivative is defined in the specification.Type: GrantFiled: August 9, 2012Date of Patent: September 10, 2013Assignee: Semiconductor Energy Laboratory Co., Ltd.Inventors: Hiroko Nomura, Sachiko Kawakami, Nobuharu Ohsawa, Satoshi Seo
-
Patent number: 8529796Abstract: The present invention relates to charge transport compositions. The invention further relates to electronic devices in which there is at least one active layer comprising such charge transport compositions.Type: GrantFiled: September 14, 2012Date of Patent: September 10, 2013Assignee: E I du Pont de Nemours and CompanyInventors: Daniel David LeCloux, Eric Maurice Smith, Ying Wang, Norman Herron, Mark A Guidry, Nora Sabina Radu
-
Publication number: 20130231344Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.Type: ApplicationFiled: January 4, 2013Publication date: September 5, 2013Applicant: CalciMedica, Inc.Inventors: Gonul Velicelebi, Kenneth A. Stauderman, Jeffrey P. Whitten, Yazhong Pei, Jianguo Cao, Zhijun Wang, Evan Rogers, Brian Dyck, Jonathan Grey
-
Publication number: 20130225591Abstract: The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylation and cell cycle regulation is implicated, such as Alzheimer's Disease and cancer.Type: ApplicationFiled: September 14, 2010Publication date: August 29, 2013Inventors: Michelle R. Machacek, Sean P. Ahearn, Eric Romeo, Tony Siu, Stephanie Chichetti, Gabriela de Almeida, Alexey A. Rivkin
-
Patent number: 8518970Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.Type: GrantFiled: January 10, 2012Date of Patent: August 27, 2013Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar
-
Patent number: 8507478Abstract: The invention relates to antibacterial compounds of formula I wherein R1 is alkoxy or halogen; U and V each independently are CH or N; is a bond or is absent; W is CH or N or, when is absent, W is CH2 or NH, with the proviso that U, V and W are not all N; A is a bond or CH2; R2 is H or, provided A is CH2, may also be OH; m and n each independently are 0 or 1; D is CH2 or a bond; G represents a phenyl group substituted once or twice in the meta and/or para position(s) by substituents selected from alkyl, (C1-C3)alkoxy and halogen, or G is a group G1 or G2 wherein Z1, Z2 and Z3 may each represent CH or N; X is N or CH and Q is O or S; it being understood that if m and n each are 0, then A is CH2; and salts of such compounds.Type: GrantFiled: October 9, 2009Date of Patent: August 13, 2013Assignee: Actelion Pharmaceuticals Ltd.Inventors: Christian Hubschwerlen, Georg Rueedi, Jean-Philippe Surivet, Cornelia Zumbrunn-Acklin
-
Publication number: 20130200352Abstract: An electroluminescent device (20) having a first layer comprising a fluorinated first organic compound with one or more fluorene residues and soluble in a fluorinated solvent, the first layer being adjacent to a second layer having second organic compound that is insoluble in a fluorinated solvent, and methods and materials for making said device.Type: ApplicationFiled: September 2, 2011Publication date: August 8, 2013Applicant: CAMBRIDGE DISPLAY TECHNOLOGY, LTD.Inventor: Jonathan Pillow
-
Publication number: 20130203656Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.Type: ApplicationFiled: May 23, 2011Publication date: August 8, 2013Applicant: PRESIDIO PHARMACEUTICALS, INC.Inventors: Min Zhong, Leping Li
-
Publication number: 20130203761Abstract: A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Inventor: Bausch & Lomb Incorporated
-
Publication number: 20130203760Abstract: A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: Bausch & Lomb IncorporatedInventor: Bausch & Lomb Incorporated
-
Publication number: 20130203756Abstract: The present invention is directed to isoindolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: October 24, 2011Publication date: August 8, 2013Inventors: Jamie L. Bunda, Christopher D. Cox, Vadim Y. Dudkin, Hannah D. Fiji, Michael J. Kelly, Mark E. Layton, Joseph E. Pero, William D. Shipe, Justin T. Sheen
-
Publication number: 20130197029Abstract: The use of a compound of formula I wherein Y is a single bond, C?O, C?S or S(O)m where m is 0, 1 or 2; the ring is a 6-membered aromatic or is a 5 or 6 membered heteroaromatic ring; Z and Z? are joined by a single or a double bond and are ?C— or —N— provided that both are not N; Ra, R1, R2, R3, R3a, R4 and R8 are specified organic groups; n is 2, 3 or 4 and p is 0-4; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs. Novel compounds are also provided.Type: ApplicationFiled: December 21, 2012Publication date: August 1, 2013Applicant: SYNGENTA CROP PROTECTION LLCInventor: Syngenta Crop Protection LLC
-
Publication number: 20130190258Abstract: Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R1, R2, R2?, R3, R4, R5, R6, R7, R8, R9 are as described herein.Type: ApplicationFiled: January 24, 2013Publication date: July 25, 2013Inventors: John CASHMAN, Mark MERCOLA, Dennis SCHADE, Masanao TSUDA
-
Patent number: 8492392Abstract: The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: GrantFiled: May 24, 2010Date of Patent: July 23, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Izzat T. Raheem, John D. Schreier
-
Publication number: 20130184284Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.Type: ApplicationFiled: July 16, 2012Publication date: July 18, 2013Inventors: William R. Ewing, Yeheng Zhu, Chongqing Sun, Yanting Huang, Maheswaran Sivasamban Karatholuvhu, Scott A. Bolton, Laxman Pasunoori, Sunil Kumar Mandal, Philip M. Sher
-
Patent number: 8486544Abstract: A quinoxaline derivative represented by Formula (I) of or Formula (II) of is provided. In Formula (I) or (II), R1, R2, R3 and R4 are, independently, hydrogen, halogen, methyl, ethyl, propyl, butyl, aryl or heteroaryl, for example phenyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl or benzoimidazolyl. The disclosure also provides an organic light-emitting diode including the quinoxaline derivative.Type: GrantFiled: August 4, 2012Date of Patent: July 16, 2013Assignee: Industrial Technology Research InstituteInventors: Heh-Lung Huang, Teng-Chih Chao, Hao-Chun Lee
-
Patent number: 8481534Abstract: 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.Type: GrantFiled: June 25, 2009Date of Patent: July 9, 2013Assignee: EnVivo Pharmaceuticals, Inc.Inventors: Amy Ripka, Gideon Shapiro, Richard Chesworth
-
Publication number: 20130165655Abstract: The present invention relates to optoelectronic materials field, and it discloses a benzodithiophene organic semiconductive material with the following structural formula (P): wherein, x+y=2; 1?x<2, 0<y?1; 1<n?100; R1, R2 are C1-C20 alkyl; R3 is selected from C1-C20 alkyl; R4, R5 are hydrogen, phenyl, C1-C20 alkyl or phenyl substituted by C1-C20 alkoxy. The present invention is also provided with preparation method and use of the benzodithiophene organic semiconductive material. The benzodithiophene containing bisphenyl siloles unit has good dissolution property, high carrier mobility, strong absorbance, wide optical absorption range, and improved utilization of sunlight, and its preparation process is simple, with high yield, and easy to operate and control.Type: ApplicationFiled: September 10, 2010Publication date: June 27, 2013Applicant: OCEAN'S KING LIGHTING SCIENCE & TECHNOLOGY CO., LTD.Inventors: Minjie Zhou, Jie Huang, Erjian Xu
-
Patent number: 8470824Abstract: A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (IV): wherein R4 is one selected from a group consisting of a hydryl group, a C1-C4 alkyl group, a C1-C4 alkoxyl group, a C1-C4 ketone group, a straight alkyl group with a branch substituted by a straight C1-C3 alkyl group, a halogen substituted C1-C4 alkyl group, and a C1-C4 alkoxyl group.Type: GrantFiled: March 23, 2011Date of Patent: June 25, 2013Assignee: National Defense Medical CenterInventor: Hsu-Shan Huang
-
Patent number: 8471017Abstract: It is an object to provide a novel bipolar organic compound. In particular, it is an object to provide a bipolar organic compound excellent in thermal stability. Further, it is another object to provide a bipolar organic compound which is electrochemically stable. A quinoxaline derivative represented by a general formula (1) is provided. Further, since the quinoxaline derivative represented by the general formula (1) is bipolar, the use of the quinoxaline derivative of the present invention allows fabrication of a light-emitting element and a light-emitting device with a low driving voltage and low power consumption. Furthermore, a light-emitting element with high luminous efficiency can be obtained.Type: GrantFiled: June 20, 2011Date of Patent: June 25, 2013Assignee: Semiconductor Energy Laboratory Co. Ltd.Inventors: Masakazu Egawa, Sachiko Kawakami, Harue Nakashima, Nobuharu Ohsawa, Satoshi Seo, Ryoji Nomura
-
Publication number: 20130158003Abstract: Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.Type: ApplicationFiled: May 26, 2011Publication date: June 20, 2013Applicant: SUNOVION PHARMACEUTICALS INCInventors: John Emmerson Campbell, Michael Charles Hewitt, Philip Jones, Linghong Xie
-
Publication number: 20130150372Abstract: This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.Type: ApplicationFiled: February 15, 2013Publication date: June 13, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hoffmann-La Roche Inc.
-
Patent number: 8461329Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.Type: GrantFiled: December 25, 2009Date of Patent: June 11, 2013Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Tetsuo Takayama, Hajime Asanuma, Daisuke Wakasugi, Rie Nishikawa, Yoshinori Sekiguchi, Madoka Kawamura, Naoya Ono, Tetsuya Yabuuchi, Takahiro Oi, Yusuke Oka, Shoichi Kuroda, Fumito Uneuchi, Takeshi Koami
-
Patent number: 8455520Abstract: Compounds of the Formula: (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating hypertension, diabetes, inflammation, atherosclerosis, pain, and the like are disclosed. Pharmaceutical compositions and methods of use are also included.Type: GrantFiled: July 11, 2008Date of Patent: June 4, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Steven L. Colletti, Hong Shen, Fa-Xiang Ding
-
Publication number: 20130131070Abstract: Provided are 1-aryl or 1-heteroaryl substituted beta-carboline compounds or indole analogs thereof having the structure: where X is NH, N—C1-C4 alkyl, S, or O; R1 is 1-naphthyl or 1-dihydroacenaphthenyl, each optionally substituted with a halogen; and R2, R3, R4, R5, R6, and R7 are independently H H, OH, halogen, CN, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, —C(O)OC1-C4 ester, —C1-C4—SO2—NH—C1-C4 sulfonamide, or phenyl with the proviso that X is NH, R1 is 1-naphthyl or 1-naphthyl substituted with a halogen and one of R5, R6, or R7 is C1-C4 alkoxy, then R2, R3, R4, R5, R6, and R7 are independently H, OH, halogen, CN, C1-C4 haloalkoxy, —C(O)OC1-C4 ester, —C1-C4—SO2—NH—C1-C4 sulfonamide, or phenyl such that at least two of R2, R3, R4, R5, R6, and R7 are other than H. Also provided are methods for inhibiting proliferation of cells associated with a cell proliferative disease by contacting the cell with the compounds provided herein.Type: ApplicationFiled: October 30, 2012Publication date: May 23, 2013Inventor: John K. Buolamwini
-
Patent number: 8445678Abstract: Disclosed are 2-quinoxalinol salen compounds and in particular 2-quinoxalinol salen Schiff-base ligands. The disclosed 2-quinoxalinol salen compounds may be utilized as ligands for forming complexes with cations, and further, the formed complexes may be utilized as catalysts for oxidation reactions. The disclosed 2-quinoxalinol salen compounds also may be conjugated to solid supports and utilized in methods for selective solid-phase extraction or detection of cations.Type: GrantFiled: October 11, 2011Date of Patent: May 21, 2013Assignee: Auburn UniversityInventors: Anne E. V. Gorden, Xianghong Wu
-
Publication number: 20130119360Abstract: Disclosed is an organic electroluminescence element comprising an anode, a cathode and a plurality of organic compound layers between the anode and the cathode, provided that one of the organic compound layers is a light emitting layer containing a phosphorescence emitting compound, wherein at least one of the organic compound layers contains a compound represented by Formula (1), wherein, X represents O or S; Y1 to Y3 each represents a hydrogen atom, a substituent or a group represented by Formula (A) disclosed un the specification, provided that at least two of Y1 to Y3 are groups represented by Formula (A), not all of Y1 to Y3 are the same group, and at least one of the groups represented by Formula (A) has Ar of a carbazolyl group, or an azacarbazolyl group containing 2 to 5 nitrogen atoms.Type: ApplicationFiled: December 13, 2012Publication date: May 16, 2013Inventors: Rie KATAKURA, Shuichi SUGITA, Eisaku KATOH, Motoaki SUGINO, Rie FUJISAWA
-
Publication number: 20130116229Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.Type: ApplicationFiled: November 8, 2012Publication date: May 9, 2013Applicants: AbbVie Inc., Abbott GmbH & Co. KGInventors: Abbott GmbH & Co.KG, AbbVie Inc.
-
Publication number: 20130115193Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: November 8, 2012Publication date: May 9, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Publication number: 20130096101Abstract: Provided herein are compounds, pharmaceutical compositions, and combination therapies for inhibition of hepatitis C.Type: ApplicationFiled: December 4, 2012Publication date: April 18, 2013Applicant: PRESIDIO PHARMACEUTICALS, INC.Inventor: PRESIDIO PHARMACEUTICALS, INC.
-
Patent number: 8420647Abstract: This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.Type: GrantFiled: January 13, 2011Date of Patent: April 16, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Henrietta Dehmlow, Shawn David Erickson, Kyungjin Kim, Rainer E. Martin, Ulrike Obst Sander, Sherrie Lynn Pietranico-Cole, Hans Richter, Christoph Ulmer
-
Patent number: 8420648Abstract: A brimonidine pamoate polymorph exhibits characteristics disclosed herein, wherein the brimonidine pamoate has the following formula The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.Type: GrantFiled: September 15, 2011Date of Patent: April 16, 2013Assignee: Bausch & Lomb IncorporatedInventors: Hongna Wang, Stephen R. Davio, Gregory L. McIntire, Michael Hall, Shazad Suchit, Jon Summersett, Brent Whitehead
-
Patent number: 8415353Abstract: Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(?NOH)NH2, —CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.Type: GrantFiled: March 3, 2009Date of Patent: April 9, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Joel M. Harris, Bernard R. Neustadt, Hong Liu, Jinsong Hao, Andrew W. Stamford
-
Patent number: 8410146Abstract: 2-pyridyl substituted imidazoles of the formula (I) as shown in claim 1, are provided, which are useful in the treatment of diseases mediated by ALK5 or ALK4 inhibitors or both.Type: GrantFiled: June 11, 2009Date of Patent: April 2, 2013Assignee: SK Chemicals Co., Ltd.Inventors: Ju Young Lee, Jae-Sun Kim, Jung-Hoon Oh, Hoe-chul Jung, Hyun Jung Lee, Sang-hwan Kang, Yong-Hyuk Kim, Sung-hoon Park, Keun-Ho Ryu, Jung Bum Yi, Hun-Taek Kim, Key-An Um, Bong-yong Lee
-
Patent number: 8404679Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.Type: GrantFiled: April 23, 2012Date of Patent: March 26, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Philippe Jablonski, Henner Knust, Andreas Koblet, Anja Limberg, Matthias Nettekoven, Hasane Ratni, Claus Riemer
-
Publication number: 20130072494Abstract: The present disclosure provides inhibitors of c-Jun N-terminal kinases (JNK) having a structure according to the following formula: or a salt or solvate thereof, wherein ring A, Ca, Cb, Z, R5, W and Cy are defined herein. The disclosure further provides pharmaceutical compositions including the compounds of the present disclosure and methods of making and using the compounds and compositions of the present disclosure, e.g., in the treatment and prevention of various disorders, such as Alzheimer's disease.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Inventors: Hing L. SHAM, Roy K. Hom, Andrei W. Konradi, Gary D. Probst, Simeon Bowers, Anh Truong, R. Jeffrey Neitz, Jennifer Sealy, Gergely Toth
-
Publication number: 20130072457Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.Type: ApplicationFiled: April 28, 2011Publication date: March 21, 2013Applicant: ASTEX THERAPEUTICS LIMITEDInventors: Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, Michael Reader, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Tom Cornelis Hortense Govaerts, Johan Erwin Edmond Weerts, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Oliver Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel
-
Patent number: 8399504Abstract: This invention relates to novel compounds of the Formula (I) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11?-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds of the Formula (I) and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.Type: GrantFiled: April 21, 2009Date of Patent: March 19, 2013Assignee: Vitae Pharmaceuticals, Inc.Inventors: David A. Claremon, Linghang Zhuang, Yuanjie Ye, Suresh B. Singh, Colin M. Tice